- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem Resistant Enterobacterales (OP0595-6)
This study looks at new medicines for serious bacterial infections like complicated urine infections, pneumonia, and tummy infections. Researchers want to see if these new treatments work better and are safer than current standard care, especially for infections resistant to common antibiotics.
For: Complicated urinary tract infection (cUTI) · acute uncomplicated pyelonephritis (AP) · hospital acquired bacterial pneumonia (HABP)France · Czechia · Greece - RecruitingPHASE2, PHASE3
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
This study, called FORMaT, is looking for the best ways to treat a serious lung infection called Mycobacterium abscessus (MABS-PD). It tests different medicines to find the most effective and safest treatments, aiming to improve how people with this condition live.
For: Pulmonary Disease Due to Mycobacteria (Diagnosis)Australia · Denmark · Israel - AuthorisedTherapeutic use (Phase IV)
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
This study looks at how well antibiotics work in very sick patients. Researchers want to make sure these important medicines reach the right levels in the body to fight serious infections effectively and safely. It's about getting the dose just right.
For: Serious infections in critically ill patients treated with antibioticsFrance